Stay updated on Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows a system revision update: added Revision: v3.4.2 and removed Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed from the Study Protocol/Statistical Analysis Plan section.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.3.4 appears and v3.3.3 is removed. This is a minor metadata update that does not change the study details.SummaryDifference0.0%

- Check62 days agoChange DetectedThe study record now includes a Locations section with multiple site locations (Arizona, California, Colorado, Florida, Maryland, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas, Washington, Alberta, Ontario, Chiba, Tokyo, Lanarkshire). The previous location listings were removed, and the revision is v3.3.3.SummaryDifference1%

- Check91 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed. This update pertains to versioning and does not modify any study data, eligibility criteria, or listed locations.SummaryDifference0.0%

- Check99 days agoChange DetectedA government funding status notice banner was removed from the page, eliminating the warning about updates and operating status. The study details and main content remain unchanged.SummaryDifference0.2%

Stay in the know with updates to Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.